

FOI2615

23/09/2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Request :

Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?

Azacitidine monotherapy

Low dose cytarabine (LoDAC) monotherapy

Venetoclax + azacitidine

Venetoclax + LoDAC

Ivosidenib

Intensive chemotherapy-based regimen

Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)

Best supportive care

Other

Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Response:

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period February 2024 to July 2024
Azacitidine monotherapy	0
LoDAC monotherapy	0
Venetoclax + azacitidine	1

Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	0
Best supportive care	Information not held in pharmacy
Other	Information not held in pharmacy

Email: Foi.Team@Southerntrust.hscni.net